Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Mesothelioma 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 9Nivolumab 3tislelizumab 2spartalizumab 2atezolizumab 2SS1(dsFv)PE38 2Ipilimumab 2talazoparib 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1entinostat 1durvalumab 1Tablets 1Polymerase Chain Reaction 1Paclitaxel 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Interleukin-2 1Immunoenzyme Techniques 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × milademetan × Other solid neoplasm × Clear all
NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

Phase 1/2 Withdrawn
DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡